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Diabetes and Driving
AMERICAN DIABETES ASSOCIATION
O f the nearly 19 million people in theU.S. with diagnosed diabetes (1), alarge percentage will seek or cur-
rently hold a license to drive. For many, a
driver’s license is essential to work; taking
care of family; securing access to public and
private facilities, services, and institutions;
interacting with friends; attending classes;
and/or performingmany other functions of
daily life. Indeed, in many communities
and areas of the U.S. the use of an automo-
bile is the only (or the only feasible or af-
fordable)means of transportation available.
There has been considerable debate
whether, and the extent to which, diabetes
may be a relevant factor in determining
driver ability and eligibility for a license.
This position statement addresses such
issues in light of current scientiﬁc and
medical evidence.
Sometimes people with a strong in-
terest in road safety, including motor vehi-
cle administrators, pedestrians, drivers,
other road users, and employers, associate
all diabetes with unsafe driving when in
fact most people with diabetes safely oper-
ate motor vehicles without creating any
meaningful risk of injury to themselves
or others. When legitimate questions arise
about the medical ﬁtness of a person with
diabetes to drive, an individual assessment of
that person’s diabetes managementdwith
particular emphasis on demonstrated abil-
ity to detect and appropriately treat poten-
tial hypoglycemiadis necessary in order
to determine any appropriate restrictions.
The diagnosis of diabetes is not sufﬁcient
to make any judgments about individual
driver capacity.
This document provides an overview
of existing licensing rules for people with
diabetes, addresses the factors that impact
driving for this population, and identiﬁes
general guidelines for assessing driver ﬁt-




betes are currently subject to a great variety
of licensing requirements and restrictions.
These licensing decisions occur at several
points and involve different levels and
types of review, depending on the type of
driving. Some states and local jurisdictions
impose no special requirements for people
with diabetes. Other jurisdictions ask driv-
ers with diabetes various questions about
their condition, including their manage-
ment regimen and whether they have ex-
perienced any diabetes-related problems
that could affect their ability to safely oper-
ate a motor vehicle. In some instances,
answers to these questions result in restric-
tions being placed on a person’s license, in-
cluding restrictions on the type of vehicle
theymay operate and/or where theymay op-
erate that vehicle. In addition, the rules for
operating a commercial motor vehicle, and
for obtaining related license endorsements
(such as rules restrictingoperationof a school
bus or transport of passengers or hazardous
materials) are quite different and in many
ways more cumbersome for people with di-
abetes, especially those who use insulin.
With the exception of commercial
driving in interstate commerce (Interstate
commercial driving is deﬁned as trade,
trafﬁc or transportation in theUnited States
between a place in a state and a place
outside of such a state, between two places
in a state through another state or a place
outside of the United States, or between
two places in a state as part of trade, trafﬁc
or transportation originating or terminat-
ing outside the state or the United States
[2]), which is subject to uniform federal
regulation, both private and commercial
driving are subject to rules determined by
individual states. These rules vary widely,
with each state taking its own approach to
determining medical ﬁtness to drive and
the issuance of licenses. How diabetes is
identiﬁed,which people aremedically eval-
uated, and what restrictions are placed on
people who have experienced hypoglyce-
mia or other problems related to diabetes
all vary from state to state.
States identify drivers with diabetes
in a number of ways. In at least 23 states,
drivers are either asked directly if they
have diabetes or are otherwise required to
self-identify if they have diabetes. In other
states drivers are asked some variation of a
question about whether they have a con-
dition that is likely to cause altered percep-
tion or loss of consciousness while driving.
In most states, when the answer to either
question is yes, the driver is required to
submit to a medical evaluation before he
or she will be issued a license.
Medical evaluation
Drivers whose medical conditions can lead
to signiﬁcantly impaired consciousness are
evaluated for their ﬁtness to continue to
drive. For people with diabetes, this typi-
cally occurswhen a person has experienced
hypoglycemia (3) behind the wheel, even if
this did not result in a motor vehicle acci-
dent. In some states this occurs as a result
of a policy to evaluate all people with di-
abetes, even if there has been no triggering
event. It can also occur when a person ex-
periences severe hypoglycemia while not
driving and a physician reports the episode
to the licensing authority. In a handful of
states, such reporting by physicians isman-
datory. In most other states physicians are
permitted to make reports but are given
discretion to determine when such reports
are necessary. Some states specify that
physiciansmay voluntarily report those pa-
tients who pose an imminent threat to pub-
lic safety because they are driving against
medical advice. Physicians and others re-
quired to make reports to the licensing au-
thority are usually providedwith immunity
from civil and criminal actions resulting
from the report.
When licensing authorities learn
that a driver has experienced an episode
of hypoglycemia that potentially affected
the ability to drive, that driver is referred
for a medical evaluation and in many
cases will lose driving privileges for a period
of time until cleared by the licensing au-
thority. This period can range from 3 to 6
months or longer. Some state laws allow for
waivers of the rules when the episode is a
one-time event not likely to recur, for
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example because of a change in medication
or episodes that occur only during sleep.
Medical evaluation procedures vary
and range from a simple conﬁrmation of
the person’s diabetes from a physician to a
more elaborate process involving a state
medical advisory board, hearings, and
presentation and assessment of medical
evidence. Some states convene medical
advisory boards with nurses and physi-
cians of different specialties who review
and make recommendations concerning
the licensing of people with diabetes and
other medical conditions. In other states,
licensing decisions are made by adminis-
trative staff with little or no medical train-
ing and with little or no review by a
medical review board or by a physician
or physicians with any relevant expertise
concerning medical conditions presented
by individual applicants.
The medical evaluation process for
commercial drivers occurs at predeter-
mined intervals, typically every 2 years.
Unlike noncommercial licenses, these
regular evaluations are not linked to
episodes of severe hypoglycemia but are
part of an ongoing ﬁtness evaluation for
jobs requiring commercial driving. The fed-
eral government has no diabetes-speciﬁc
restrictions for individuals who manage
their disease with diet, exercise, and/or
oral medication. It offers an exemption
program for insulin-using interstate com-
mercial drivers and issues medical certiﬁ-
cates to qualiﬁed drivers. Factors in the
federal commercial driving medical evalu-
ation include a review of diabetes history,
medications, hospitalizations, blood glu-
cose history, and tests for various com-
plications and an assessment of driver
understanding of diabetes and willingness
to monitor their condition.
SCIENCE OF DIABETES AND
DRIVINGdHypoglycemia indicating
an impaired ability to drive, retinopathy
or cataract formation impairing the vision
needed to operate a motor vehicle, and
neuropathy affecting the ability to feel foot
petals can each impact driving safety (4).
However, the incidence of these conditions
is not sufﬁciently extensive to justify re-
striction of driving privileges for all drivers
with diabetes. Driving mishaps related to
diabetes are relatively infrequent for most
drivers with diabetes and occur at a lower
rate than mishaps of many other drivers
with conditions that affect driving perfor-
mance and that are tolerated by society.
However, just as there are some pa-
tients with conditions that increase their
risk of incurring driving mishaps, such as
unstable coronary heart disease, obstruc-
tive sleep apnea, epilepsy, Parkinson’s
disease, or alcohol and substance abuse,
there are also some drivers with diabetes
that have a higher risk for driving mis-
haps. The challenges are to identify high-
risk individuals and develop measures to
assist them to lower their risk for driving
mishaps.
Understanding the risk of diabetes
and driving
In a recent Scottish study, only 62% of
health care professionals suggested that
insulin-treated drivers should test their
blood glucose before driving; 13% of health
care professionals thought it safe to drive
with blood glucose,72mg/dL (4mmol/L),
and 8% did not know that impaired aware-
ness of hypoglycemia might be a contrain-
dication to driving (5). It is important that
health care professionals be knowledgeable
and take the lead in discussing risk reduc-
tion for their patients at risk for hypoglyce-
mia. In a large international study, nearly
half of drivers with type 1 diabetes and
three-quarters of those with type 2 diabetes
had never discussed driving guidelines with
their physician (8).
A meta-analysis of 15 studies sug-
gested that the relative risk of having a
motor vehicle accident for people with
diabetes as a whole, i.e., without differen-
tiating those with a signiﬁcant risk from
those with little or no risk, as compared
with the general population ranges be-
tween 1.126 and 1.19, a 12–19% in-
creased risk (6). Some published studies
indicated that drivers with type 1 diabetes
have a slightly higher risk, with a relative
risk ratio of ;2 (7,8,9), but this was not
conﬁrmed by other studies (10). Two stud-
ies even suggested that there is no increased
risk associated with insulin-treated diabe-
tes (11,12), but the methodologies used
have been criticized (13).
This increased risk of collisions must
be interpreted in the light of society’s tol-
erance of other and much higher–risk
conditions. For example, 16-year-old
males have 42 times more collisions than
35- to 45-year-old women. If the heaviest
car collides with the lightest car, the driver
of the latter is 20 times more likely to be
killed than the driver of the former. The
most dangerous rural highways are 9.2
times more dangerous than the safest urban
highways. Driving at 1:00 A.M. on Sunday is
142 times more dangerous than driving at
11:00 A.M. (7). Driverswith attention deﬁcit/
hyperactivity disorder have a relative risk
ratio of;4 (14), whereas those with sleep
apnea have a relative risk of ;2.4 (15). If
society tolerates these conditions, it would
be unjustiﬁed to restrict the driving priv-
ileges of an entire class of individuals who
are at much lower risk, such as drivers
with diabetes.
The most signiﬁcant subgroup of
persons with diabetes for whom a greater
degree of restrictions is often applied is
drivers managing their diabetes with in-
sulin. Yet, when the type of diabetes is
controlled for, insulin therapy per se has
not been found to be associated with in-
creased driving risk (3,16,17). While im-
paired awareness of hypoglycemia has
been found to relate to increased incidence
of motor vehicle crashes in some studies
(12), it has not been found to be a relevant
variable in other studies (4,7,23). The sin-
gle most signiﬁcant factor associated with
driving collisions for drivers with diabetes
appears to be a recent history of severe hy-
poglycemia, regardless of the type of diabe-
tes or the treatment used (1,3,18–21).
The American Diabetes Association
Workgroup on Hypoglycemia deﬁned se-
vere hypoglycemia as low blood glucose
resulting in neuroglycopenia that disrupts
cognitive motor function and requires the
assistance of another to actively administer
carbohydrate, glucagon, or other resuscita-
tive actions (22). In a prospective multicen-
ter study of 452 drivers with type 1 diabetes
followed monthly for 12 months, 185 par-
ticipants (41%) reported a total of 503 epi-
sodes of moderate hypoglycemia (where
the driver could still treat him/herself but
could no longer drive safely) and 23 partic-
ipants (5%) reported 31 episodes of severe
hypoglycemia (where the driver was unable
to treat him/herself) while driving (21).
Conversely, the Diabetes Control andCom-
plications Trial (DCCT) group reported 11
motor vehicle accidents in 714 episodes of
severe hypoglycemia, a rate of 1.5% (23).
The signiﬁcant impact of moderate
hypoglycemia while driving is supported
by multiple studies demonstrating that
moderate hypoglycemia signiﬁcantly and
consistently impairs driving safety (24–26)
and judgment (27,28) as towhether to con-
tinue to drive or to self-treat (29,30) under
such metabolic conditions. In one study,
25% of respondents thought it was safe to
drive even when blood glucose was ,70
mg/dL (3.9 mmol/L) (31).
While signiﬁcant hyperglycemia may
impair cognitive, motor, and perceptual
functioning (32–35), there is only one re-
port suggesting extreme hyperglycemia
can impact driving safety (36). Thus,
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efforts to equate hyperglycemia with driv-
ing impairment are currently not scientif-
ically justiﬁed.
Individual differences
Eighty percent of episodes of severe hy-
poglycemia affect about 20% of people
with type 1 diabetes (37–39). Available
data suggest that a small subgroup of driv-
ers with type 1 diabetes account for the
majority of hypoglycemia-related colli-
sions (9,30,40). When 452 drivers with
type 1 diabetes were followed prospec-
tively for a year, baseline reports of prior
episodes of mild symptomatic hypoglyce-
mia while driving or severe hypoglycemia
while driving, hypoglycemia-related driv-
ing mishaps, or hypoglycemia-related
collisions were associated with a higher
risk of driving mishaps in the following
12 months by 3, 6, 6, and 20%, respec-
tively. Risk increased exponentially with
additional reported episodes: If individu-
als had two episodes of severe hypoglyce-
mia in the preceding 12 months their risk
increased to 12%, and two collisions in
the previous 2 years increased their risk
by 40%. The strongest predictors in-
volved a history of hypoglycemia while
driving (21). Laboratory studies that com-
pared drivers with type 1 diabetes who
had no history of hypoglycemia-related
driving mishap in the past year to those
who had more than one mishap found
that those with a history of mishaps: 1)
drove signiﬁcantly worse during progres-
sive mild hypoglycemia (70–50 mg/dL,
3.9–2.8 mmol/L) but drove equally well
when blood glucose was normal (euglyce-
mia); 2) had a lower epinephrine response
while driving during hypoglycemia, 3)
were more insulin sensitive, and 4) demon-
strated greater difﬁculties with working
memory and information processing speed
during euglycemia and hypoglycemia
(24,40,41). Thus, a history of mishaps
should be used as a basis for identifying
insulin-managed drivers with elevated
risk of future mishaps. Such individuals
are appropriately subjected to additional
screening requirements.
Four studies have demonstrated that
Blood Glucose Awareness Training
(BGAT) reduces the occurrence of colli-
sions and moving vehicle violations while
improving judgment about whether to
drive while hypoglycemic (42–45). BGAT
is an 8-week psycho-educational training
program designed to assist individuals
with type 1 diabetes to better anticipate,
prevent, recognize, and treat extreme
blood glucose events. This intervention
can be effectively delivered over the inter-
net (46). Diabetes Driving (diabetesdriv-
ing.com), a program funded by the
National Institutes of Health, is another
internet-based tool to help assess the
risk of driving mishaps and assist high-
risk drivers to avoid hypoglycemia while
driving and to better detect and manage
hypoglycemia if it occurs while driving.
RECOMMENDATIONS
Identifying and evaluating diabetes
in drivers
Individuals whose diabetes poses a sig-
niﬁcantly elevated risk to safe driving
must be identiﬁed and evaluated prior to
getting behind the wheel. Because people
with diabetes are diverse in terms of the
nature of their condition, the symptoms
they experience, and the measures they
take to manage their diabetes, it is impor-
tant that identiﬁcation and evaluation pro-
cesses be appropriate, individualized, and
based not solely on a diagnosis of diabetes
but rather on concrete evidence of actual
risk. Laws that require all people with
diabetes (or all people with insulin-treated
diabetes) to be medically evaluated as a
condition of licensure are ill advised be-
cause they combine people with diabetes
into one group rather than identifying
those drivers who may be at increased risk
due to potential difﬁculties in avoiding
hypoglycemia or the presence of compli-
cations. In addition, the logistics of regis-
tering and evaluating millions of people
with diabetes who wish to drive presents
an enormous administrative and ﬁscal bur-
den to licensing agencies. States that require
drivers to identify diabetes should limit
the identiﬁcation to reports of diabetes-
related problems.
To identify potentially at-risk drivers, a
short questionnaire can be used to ﬁnd
those drivers who may require further
evaluation. The questionnaire should ask
whether the driver has, within the past 12
months, lost consciousness due to hypo-
glycemia, experienced hypoglycemia that
required intervention from another per-
son to treat or that interfered with driving,
or experienced hypoglycemia that devel-
oped without warning. The questionnaire
should also query about loss of visual
acuity or peripheral vision and loss of
feeling in the right foot. Inasmuch as
obstructive sleep apnea is more common
in people with type 2 diabetes than in the
nondiabetic population, patients should
be queried about falling asleep during the
day. Any positive answer should trigger an
evaluation to determine whether restric-
tions on the license or mechanical mod-
iﬁcations to the vehicle (e.g., hand
controls for people with an insensate
foot) are necessary to ensure public safety.
It is ill-advised to determine risk for
driving mishaps based on a driver’s gly-
cosylated hemoglobin because episodic
transitions into hypoglycemia, not average
blood glucose, increases risk of driving
mishaps.
Evaluation of drivers with diabetes
must include an assessment by the treat-
ing physician or another diabetes special-
ist who can review recent diabetes history
and provide to the licensing agency a
recommendation about whether the
driver has a condition that impairs his
or her ability to safely operate a motor
vehicle. The treating physician or another
physician who is knowledgeable about
diabetes is the best source of information
concerning the driver’s diabetes manage-
ment and history. The input of such a
physician is essential to assess a person’s
diabetes management and determine
whether operation of a motor vehicle is
safe and practicable. If questions arise
concerning the safe driving ability of a
person with chronic complications of di-
abetes (e.g., retinopathy or neuropathy),
the individual should be referred to a spe-
cialist with expertise in evaluating the
diabetes-related problem for speciﬁc rec-
ommendations.
Physicians should be requested to
provide the following information: 1)
whether the driver has had an episode of
severe hypoglycemia requiring interven-
tion from another person within the pre-
vious 2 years (and when this happened);
2) whether there was an explanation for
the hypoglycemia; 3) whether the driver is
at increased risk of severe hypoglycemia;
4) whether the driver has the ability to
recognize incipient hypoglycemia and
knows how to take appropriate corrective
action; 5) whether the driver provides ev-
idence of sufﬁcient self-monitoring of
blood glucose; 6) whether the driver has
any diabetes-related complications affect-
ing safe driving that need further assess-
ment; and 7) whether the driver has a
good understanding of diabetes and its
treatment, has been educated on the
avoidance of hypoglycemia while driving,
and is willing to follow a suggested treat-
ment plan.
When evaluating a driverwith a history
of severe hypoglycemia, impaired hypogly-
cemia awareness, or a diabetes-related mo-
tor vehicle accident, it is necessary to
care.diabetesjournals.org DIABETES CARE, VOLUME 35, SUPPLEMENT 1, JANUARY 2012 S83
American Diabetes Association
investigate the reasons for the hypoglyce-
mia and to determine whether it is a
function of the driver’s treatment regimen
or lifestyle, a psychological reaction to the
management of their diabetes, or the nor-
mal course of diabetes. Appropriate clini-
cal interventions should be instituted.
Licensing decisions following
evaluation
Drivers with diabetes should only have a
license suspended or restricted if doing so
is the only practical way to address an
established safety risk. Licensing deci-
sions should reﬂect deference to the pro-
fessional judgment of the evaluating
physician with regard to diabetes, while
also balancing the licensing agency’s need
to keep the roads and the public safe.
States should have medical advisory
boards whose role is to assess potential
driving risks based on continually up-
dated medical information, to ensure
that licensing agency staff is prepared to
handle diabetes licensing issues, and to
make recommendations relevant to indi-
vidual drivers. State medical advisory
boards should have representation by
health care professionals with expertise
in treating diabetes, in addition to the in-
formation provided by the driver’s treating
physician, prior to making licensing deci-
sions for people with diabetes. Where the
medical advisory board does not have a
permanent member with expertise in di-
abetes, such an expert should be consulted
in cases involving restrictions on a driver
with diabetes.
As discussed above, a history of hy-
poglycemia does not mean an individual
cannot be a safe driver. Rather, when
there is evidence of a history of severe
hypoglycemia, an appropriate evaluation
should be undertaken to determine the
cause of the low blood glucose, the cir-
cumstances of the episode, whether it was
an isolated incident, whether adjustment
to the insulin regimen may mitigate the
risk, and the likelihood of such an episode
recurring. It is important that licensing
decisions take into consideration contrib-
utory factors that may mitigate a potential
risk, and that licensing agencies do not
adopt a “one strike” approach to licensing
people with diabetes. Drivers with diabe-
tes must be individually assessed to deter-
mine whether their diabetes poses a safety
risk. The mere fact that a person’s diabetes
has come to the attention of the licensing
agencydwhether by a report or because
of an accidentdshould not itself pre-
determine a licensing decision.
Generally, severe hypoglycemia that
occurs during sleep should not disqualify
a person from driving. Hypoglycemia that
occurswhile theperson is not driving should
be examined to determine if it is indicative
of a larger problem or an event that is not
likely to recur while the person is behind
the wheel of a car (e.g., hypoglycemia that
occurs during an intense bout of exercise).
Some episodes of severe hypoglycemia can
be explained and corrected with the assis-
tance of a diabetes health care professional,
e.g., episodes that occur because of a
change in medication. However, recurrent
episodes of severe hypoglycemia, deﬁned
as two or more episodes in a year, may
indicate that a person is not able to safely
operate a motor vehicle.
States whose licensing rules lead to a
suspension of a driver’s license following
an episode of hypoglycemia should allow
for waiver of these rules when the hypo-
glycemia can be explained and addressed
by the treating physician and is not likely
to recur. For example, waivers may be ap-
propriate following hypoglycemia that
happens as a result of a change in medi-
cation or during or concurrent with ill-
ness or pregnancy. Licensing agencies
may request documentation from the
physician attesting that the patient meets
the conditions for a waiver (which may
include, among other requirements, edu-
cation on diabetes management and
avoidance of hypoglycemia).
Drivers with a suspended license be-
cause of factors related to diabetes should
be eligible to have their driver’s license re-
instated following a sufﬁcient period of
time (usually no more than 6 months)
upon advice from the treating physician
that the driver has made appropriate ad-
justments and is adhering to a regimen
that has resulted in correction of the prob-
lems that led to the license suspension. Fol-
lowing reinstatement of driving privileges,
periodic follow-up evaluation is necessary
to ensure that the person remains safely
able to operate a motor vehicle.
People who experience progressive
impairment of their awareness of hypo-
glycemia should consult a health care
provider to determine whether it is safe
to continue driving with proper measures
to avoid disruptive hypoglycemia (such as
testing blood glucose before driving and
at regular intervals in the course of a
journey lasting more than 30–60 min). If
the driver is able to make adjustments to
improve awareness or prevent disruptive
hypoglycemia while driving, there should
not be license restrictions. Continuous
glucose monitoring may also be beneﬁcial,
particularly when noting the direction of
the glucose trend. If this technology is
used, the person using the device needs
to appreciate that any action taken (e.g.,
additional carbohydrate consumption)
needs to be based on a blood glucose mea-
surement.
The determination of which disquali-
ﬁed drivers should be reevaluated and
when this should be done should bemade
on an individual basis considering factors
such as the circumstances of the disqual-
ifying event and changes in medication
and behavior that have been implemented
by the driver. When an assessment deter-
mines that the driver should be evaluated
at some point in the future, the driver’s
physician should be consulted to deter-
mine the length of the reevaluation pe-
riod. A driver with diabetes should not
be kept in an endless cycle of reevaluation
if there is no longer a signiﬁcantly ele-
vated safety risk.
The determination of medical ﬁtness
to drive should be a clinical one, weighing
the various factors noted above. Decisions
about whether licensing restrictions are
necessary to ensure safety of the traveling
public are ultimately determined by the
licensing agency, taking into account the
clinical determination of medical ﬁtness.
Physician reporting
Although the concept behind mandatory
physician reporting laws is to keep roads
safe by eliminating unacceptable risk
from impaired driving, such laws have
the unintended consequence of discour-
aging people with diabetes from discus-
sing their condition frankly with a
physician when there is a problem that
needs correction due to fear of losing their
license. Patients who are not candid with
their physicians are likely to receive in-
ferior treatment and therefore may expe-
rience complications that present a
driving risk. In addition to the negative
effect that mandatory reporting has on the
physician-patient relationship, there is
no evidence that mandatory physician
reporting reduces the crash rate or im-
proves public safety (47).
Physicians should be permitted to
exercise professional judgment in decid-
ing whether and when to report a patient
to the licensing agency for review of
driving privileges. States that allow physi-
cians to make such reports should focus
onwhether the driver’s mental or physical
condition impairs the patient’s ability to
exercise safe control over a motor vehicle.
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Reports based solely on a diagnosis of di-
abetes, or tied to a characterization that
the driver has a condition involving lapses
of consciousness, are too broad and do
not adequately measure individual risk.
Ultimately, reports must be left to the dis-
cretion of the physician, using profes-
sional judgment about whether the
patient poses a safety risk. Further, in or-
der to protect the physician-patient rela-
tionship and ensure the open and honest
communication that ultimately promotes
safety, it is important that physicians be
immunized from liability, both for mak-
ing reports and not making reports.
Patient education and clinical
interventions
It is important that health care professio-
nals be knowledgeable and take the lead in
discussing risk reduction for their patients
at risk for disruptive hypoglycemia. This
starts with health care professionals being
conversant with safe practices, particularly
for those patients at increased risk for
diabetes-related incidents. Perhaps the
most important aspect of encouraging peo-
ple with diabetes to be safe drivers is for
health care professionals who treat diabetic
drivers to provide education about driving
with diabetes and potential risks associated
with patients’ treatment regimens. When
that regimen includes the possibility of hy-
poglycemia, education should include in-
struction on avoiding and responding to
hypoglycemia, discussion about the pa-
tient’s vulnerability for driving mishaps,
and ongoing learning to ensure that pa-
tients have knowledge of when it is and is
not safe for them to drive. For example, the
risks of driving under the inﬂuence of alco-
hol are well known, but the delayed hypo-
glycemic effects of even moderate alcohol
intake are not, and alcohol exacerbates the
cognitive impairment associated with hy-
poglycemia (48). Inasmuch as hypoglyce-
mia can be mistaken for intoxication, and
both increase the risk of motor vehicle ac-
cidents, patients should be counseled to
test glucose more frequently for several
hours after moderate alcohol intake.
When a patient has complications of dia-
betes, it is important for the physician to
discuss with the driver the effect of those
complications, if any, on driving ability.
Physicians and other health care pro-
fessionals who treat people with diabetes
should regularly discuss the risk of driving
with low blood glucose with their patients.
Clinical visits should include review of
blood glucose logs and questions to the
patient about symptoms associated with
high or low blood glucose levels and what
the patient did to treat those levels. Allow-
ing health care professionals to exercise
professional judgment about the informa-
tion they learn in these patient conversa-
tions will encourage candid sharing of
information and lead to improved patient
health and road safety.
Clinical interventions in response to
hypoglycemia vary by individual but may
include strategies for the frequency and
timing of blood glucose monitoring,
medication dosage changes, and estab-
lishing more conservative glucose targets
if there is a history of severe hypo-
glycemia. Certain people who have a
history of severe hypoglycemia may be
encouraged by their health care provider
to use continuous glucose monitoring
systems that enable them to detect a
trend toward hypoglycemia before glu-
cose levels fall to a level that will affect
safe driving.
Of note, special care should be taken to
prevent hypoglycemia while operating any
vehicle in driverswith type 1 diabetes and in
thosewith type 2 diabeteswho are at risk for
developing hypoglycemia. They should be
instructed to always check blood glucose
before getting behind the wheel and at
regular intervals while driving for periods
of 1 h or greater. Consideration should be
given to factors that may predict a fall in
blood glucose, including time of insulin
administration, timing of the last meal or
food ingestion, and exercise type, duration,
intensity, and timing. Low blood glucose
values should be treated immediately and
appropriately, and the driver should not
drive until blood glucose is in a safely
acceptable range, usually after 30–60
min because of delayed recovery of cog-
nitive function.
People with diabetes who are at risk
for disruptive hypoglycemia should be
counseled to: 1) always carry a blood glu-
cose meter and appropriate snacks,
including a quick-acting source of sugar
(such as juice, nondiet soda, hard candy,
or dextrose tablets) as well as snacks with
complex carbohydrate, fat, and protein
(e.g., cheese crackers), in their vehicle;
2) never begin an extended drive with
low normal blood glucose (e.g., 70–90
mg/dL) without prophylactic carbohy-
drate consumption to avoid a fall in blood
glucose during the drive; 3) stop the ve-
hicle as soon any of the symptoms of low
blood glucose are experienced and mea-
sure and treat the blood glucose level; and
4) not resume driving until their blood
glucose and cognition have recovered.
CONCLUSIONdIn summary, people
with diabetes should be assessed individ-
ually, taking into account each individu-
al’s medical history as well as the potential
related risks associated with driving.
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